Das Arun 4

What Happened
Das Arun, Chief Business Officer of Cabaletta Bio (CABA), was granted a derivative award covering 175,000 shares on 2026-03-02. The filing reports an acquisition at $0.00 (reported value $0), indicating an equity award/option-style grant rather than an open-market purchase or sale. The award does not result in immediate common‑share ownership until vesting/exercise.

Key Details

• Transaction date: 2026-03-02 (filing dated 2026-03-02) — appears timely.
• Grant: 175,000 derivative shares; reported price $0.00; total reported consideration $0.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting (footnote): 25% vests on March 1, 2027; remaining 75% vests in 12 substantially equal quarterly installments thereafter, subject to continued service.
• Transaction code: A = grant/award/other acquisition (derivative).

Context
This is a common form of executive equity compensation (stock options or RSUs-like derivative award). Because it’s a derivative grant with multi-year vesting, it does not represent an immediate change in voting or selling power and should not be interpreted as a market buy/sell signal by itself.